S-E. Al-Batran

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

Akin Atmaca, S-E. Al-Batran, Alexander Maurer et al. · British Journal of Cancer · 2007 · 185 citations · Full text

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Sebastian Stintzing, Lisa Miller‐Phillips, Dominik Paul Modest et al. · European Journal of Cancer · 2017 · 138 citations

First-line Efficacy, Cetuximab Versus Folfiri, Ras Mutations +11

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

Heikki Joensuu, Mikael Eriksson, J. Hatrmann et al. · Journal of Clinical Oncology · 2011 · 79 citations

Surgical Oncology, Cancer Management, Immunology +16

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Yelena Y. Janjigian, S-E. Al-Batran, Zev A. Wainberg et al. · Annals of Oncology · 2023 · 77 citations

Tumor Biology, Surgical Oncology, Oncology +13

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Nicole Haense, Akin Atmaca, Claudia Pauligk et al. · BMC Cancer · 2016 · 62 citations · Full text